Terns Pharmaceuticals has restructured a key licensing deal with China's Hansoh, gaining exclusive worldwide rights for its TERN-701 oncology drug outside Greater China. The strategic move, coupled with a recent analyst price target surge, signals the company's aggressive push into international markets.
Audius SE (FRA:3ITN) shares jumped 13% last week, prompting a closer look at whether the rally is backed by the company's financial health or driven by broader market sentiment.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
With its blockbuster Humira era in the rearview, AbbVie is betting big on its next-generation immunology drugs and a deep pipeline to drive growth and maintain its crown among Dividend Kings.
Alibaba Group has pledged 3 billion yuan ($431 million) to promote its Qwen AI app during the upcoming Lunar New Year holiday, significantly outpacing similar campaigns by rivals Tencent and Baidu and marking a major escalation in China's competitive AI landscape.
The Hong Kong Monetary Authority (HKMA) is poised to grant its inaugural stablecoin issuer licenses in March, with approvals expected for only a select few firms. The move transitions the city's digital asset framework from sandbox testing to a formally regulated market, focusing on stringent risk controls and credible use cases.
A new proposal from Ethereum's Vitalik Buterin to refine creator tokens using DAOs and prediction markets has met with sharp criticism from Dogecoin's Billy Markus, who dismisses the entire model as destined to fail.
Leading Solana DEX aggregator Jupiter has finalized a $35 million strategic investment from ParaFi Capital, with the landmark deal to be settled entirely in its native stablecoin, JupUSD. The move signals strong institutional validation and a push for JupUSD adoption.
Despite a meteoric long-term rise, D-Wave Quantum's recent sharp decline highlights the extreme risks and towering valuations inherent in the speculative quantum computing sector. Investors face a critical decision.
Amidst recent market volatility driven by regional tensions, a closer look reveals companies with strong fundamentals demonstrating remarkable resilience and growth potential. We examine three such firms that are navigating the uncertainty and positioning themselves for the future.
A Florida family’s dream home purchase turned into a financial nightmare after discovering a hidden $45,000 lien attached to solar panels advertised as ‘free.’ The case highlights critical pitfalls in the booming residential solar market.
Enterprise Financial Services Corp. (EFSC) reported fourth-quarter revenue that surpassed analyst forecasts, driven by net interest income expansion and robust deposit growth. The regional bank's results were bolstered by recent branch acquisitions and disciplined pricing, though investors are now watching how it navigates potential rate cuts and credit quality.
Fidelity data reveals the average millennial 401(k) balance stands at $67,300. While the figure may seem modest, financial experts argue it represents a solid foundation for a generation that entered the workforce during economic turmoil.
Tether's dominance has surged to a two-year high, breaking a key resistance level. Analysts interpret this as a signal that investors are fleeing to safety, suggesting the crypto market's slump may have further to run before a true bottom is found.
Solana's leading DEX aggregator Jupiter announces a landmark integration with prediction market giant Polymarket, alongside securing a $35 million strategic investment from ParaFi Capital, signaling a major push into on-chain forecasting.
Short interest in beverage giant Constellation Brands has declined, signaling a potential shift in trader sentiment. However, the level remains elevated compared to industry rivals, highlighting ongoing debate over the stock's valuation amid shifting consumer trends.
Following a recent pullback in its share price, AutoNation (AN) is back under the microscope. While short-term trading shows weakness, the company's robust multi-year returns present a compelling valuation puzzle for market watchers.
As markets navigate a new year, analysts are eyeing potential outperformers. Amazon, BeOne Medicines, and Enterprise Products Partners emerge as compelling picks, each backed by distinct catalysts from AI to biotech breakthroughs.
Recent share price weakness at French construction giant Compagnie de Saint-Gobain has investors questioning its valuation. While a key model suggests the stock is fairly priced, its low P/E ratio compared to peers hints at potential undervaluation, setting the stage for a nuanced debate on the stock's true worth.
Harmony Biosciences CFO Sandip Kapadia has liquidated his entire direct stake in the company, a move that contrasts sharply with the firm's robust financial performance and bullish $1 billion revenue target for its flagship drug WAKIX by 2026. While the sales were pre-planned, the timing fuels debate on insider confidence versus corporate optimism.
